Veterinary Therapeutic Protein and Peptide Ribosomal Display Platform

R&D Solutions

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veterinary Therapeutic Protein and Peptide Ribosomal Display Platform

Inquiry Now

Overview Ribosomal Display Services Features Service Workflow Related Research Why Choose Us Case Study FAQs

BioVenic provides a ribosomal display platform for the discovery and evolution of veterinary therapeutic proteins and peptides, supporting the identification of high-affinity binders against specific animal disease targets across biotechnology and pharmaceutical applications. Our platform covers the complete cell-free workflow—diverse DNA library construction, cell-free transcription/translation to form protein-ribosome-mRNA (PRM) complexes, affinity selection with in situ RT-PCR recovery, full-length DNA regeneration, and cloning, expression, and screening of candidate binders. We support tailored, high-throughput discovery programs through multiple selection rounds, comparative binding analyses, detailed reporting, and continuous technical support to deliver validated candidates for downstream development.

Ribosomal Display Platform Overview

Ribosomal display platform is an innovative in vitro cell-free technology capable of protein and peptide production and evolution with exceptional diversity up to 10¹⁵. This platform leverages proprietary prokaryotic and eukaryotic display technologies. BioVenic provides a thorough ribosomal display cycle comprising five essential steps. Generally, several rounds of screening are required to separate the veterinary therapeutic proteins and peptides that bind disease targets with high affinity. The ribosomal display screens larger libraries and increases the possibility of the discovery of novel proteins and peptides since the whole process in process in vitro without the need for cell cloning.

Fig.1 The cycle of ribosomal display at BioVenic for the discovery of veterinary therapeutic proteins and peptides. (BioVenic Original) Fig.1 The ribosomal display cycle of veterinary therapeutic protein and peptide discovery. (BioVenic Original)

Ribosomal Display Services

	Description	Services
Library Construction	Create a diverse library of DNA sequences that encode the proteins or peptides of interest.	Augment the genetic diversity of the libraries to increase the likelihood of finding highly effective and unique binders. Provide quickly generated PCR constructs for early-stage research, facilitating fast iteration and testing.
Cell Generation of PRMs	The DNA library is transcribed and translated in a cell-free system to produce PRM complexes. The mRNA remains attached to the ribosome, which is still bound to the newly synthesized protein/peptide.	Offer high-fidelity protein-RNA matching, to ensure precise interactions between protein/peptide and RNA.
*Affinity Selection & In Situ* RT-PCR Recovery**	The PRM complexes are exposed to an immobilized ligand, allowing proteins with high affinity for the ligand to bind. After affinity selection, the mRNA from the bound PRM complexes is reverse-transcribed into cDNA. This cDNA serves as a template for PCR amplification.	Identify proteins or peptides with high affinity and specificity to certain targets relevant to veterinary diseases. Utilize in situ RT-PCR to recover and amplify the RNA of bound peptides or proteins, ensuring that successful binders are captured for further analysis. Conduct comparative analyses to assess the binding efficiency and specificity of various candidates for clients. Optimize the recovery process to ensure maximum yield of target-bound complexes.
Regeneration of Full-Length DNA Constructs	The recovered cDNA is used to regenerate the full-length PCR construct, which can be used in subsequent selection cycles to further refine and enrich high-affinity binders.	Provide services to regenerate full-length DNA constructs from selected RNA, facilitating multiple rounds of selection. Facilitate the regeneration of full-length constructs for repetitive screening, enhancing the throughput of discovery cycles.
Cloning, Expression, & Screening	Selected DNA sequences encoding proteins or peptides are cloned into expression vectors, expressed in suitable systems, and screened for desired properties.	Utilize advanced technologies to screen large numbers of clones for optimal binders. Conduct rigorous screening processes to evaluate the efficacy, specificity, and stability of proteins or peptides, identifying candidates most likely to succeed in veterinary therapeutic protein and peptide development.

Ribosomal Display Platform Features

Ribosomal display owns libraries with large diversity sizes (approximately 10¹⁵).
The protein remains attached to its encoding mRNA via the ribosome, linking the genetic information directly to the protein's or peptide's physical characteristics.
In vitro technique that does not rely on living cells, allowing for the direct translation of mRNA into protein-ribosome complexes.
Scalable for both small-scale research applications and large-scale industrial processes.
Minimize the bias introduced by cellular systems, offering a more accurate representation of protein characteristics.

BioVenic also provides other cell-free platforms to discover therapeutic proteins and peptides, including mRNA display, and DNA display. Please get access to other cell-free platforms via the following links:

Service Workflow

Ribosomal display technology at BioVenic starts with a comprehensive consultation to understand client goals and tailor services. We craft diverse ribosome libraries, either custom-built or selected from existing collections, targeted specifically at veterinary diseases. This approach ensures a broad capture of potential binders. Our screening process includes multiple rounds of panning that demonstrate strong affinity and specificity for the intended target. Selected promising candidates are then subjected to sequencing and in-depth characterization to evaluate their binding properties. Ultimately, we provide detailed reports and continuous support, seamlessly integrating the developed proteins or peptides into the client's research or product pipelines, fostering advances in both scientific understanding and therapeutic applications. BioVenic also offers a one-stop solution for the development of veterinary therapeutic proteins and peptides through its exhaustive phage display services, designed to meet the specific needs of each client.

Fig.2 The service workflow of veterinary therapeutic protein and peptide ribosomal display. (BioVenic Original) Fig.2 The procedural framework of ribosomal display services for veterinary therapeutic proteins and peptides. (BioVenic Original)

Related Research

To discover novel inhibitors targeting the intrinsically disordered and historically "undruggable" MYC oncoprotein, researchers integrated tyrosinase-mediated enzymatic cyclization with high-throughput mRNA display technology to construct and screen combinatorial macrocyclic peptide libraries. Direct physical interaction with MYC was validated using bio-layer interferometry (BLI), which confirmed dose-dependent binding with dissociation constants in the micromolar range. To address the inherent cell-permeability constraints of cyclic peptides, the lead sequences were conjugated at the C-terminus with an HIV-1 TAT-derived cell-penetrating peptide sequence (GRKKRRQRRR), which enhanced intracellular uptake and yielded antiproliferative IC50 values of 1–3 μM against MYC-dependent cancer cell lines, whereas corresponding uncyclized linear counterparts demonstrated no significant efficacy. Furthermore, transcriptomic profiling via RNA sequencing confirmed that treatment with the optimized conjugate (TAT-CP5) selectively downregulates canonical downstream MYC target genes, demonstrating that enzymatically cyclized peptides enriched by mRNA display can successfully traverse cell membranes to disrupt oncogenic transcription factor activity.

Fig. 3 Schematic overview. (Chen, 2026) (OA Literature) Fig. 3 Schematic overview of the mRNA display selection for MYC-binding macrocyclic peptides.¹

Why Choose Us?

In Vitro Environment

All steps are conducted in a test tube, allowing precise control over experimental conditions.

Facilitated Evolution

Enable directed evolution of proteins through mutations, with immediate screening and evaluation variants.

High-Throughput Screening

Rapid and efficient identification of candidates with strong affinity to disease targets technologies.

Rapid Iteration

Allows for faster screening of large libraries by eliminating the need for cell transformation and cultivation.

One-Stop Solution

Comprehensive services from initial consultation to production, and development.

Case Study: Affinity Maturation of a Veterinary Therapeutic Peptide by Ribosomal Display

To improve a starting peptide binder against a veterinary disease-relevant target, which displayed modest affinity and dissociated too quickly for therapeutic use, researchers applied a cell-free ribosomal display platform to affinity maturation: the parent peptide was diversified into a high-complexity DNA library, transcribed and translated in vitro to form Protein-Ribosome-mRNA complexes, and subjected to five rounds of affinity selection with increasing stringency. Bound mRNAs were recovered by in situ RT-PCR and cycled back for further enrichment. As shown in the binding-kinetics trace, the parent peptide produced the lowest binding response and the fastest dissociation, the Round 3 variant showed a higher response with a moderate off-rate, and the Round 5 optimized variant achieved the highest response combined with the slowest dissociation—corresponding to roughly an 8–10 fold overall affinity improvement. Sequence analysis of Round 5 clones revealed recurring substitutions, confirming convergent evolution toward a preferred binding motif.

Fig. 4 Binding Kinetics (BioVenic Original) Fig. 4 Binding Kinetics

Frequently Asked Questions

Q1. What is the main advantage of using the ribosomal display platform for veterinary protein and peptide screening?

A: By keeping the genotype and phenotype coupled via the ribosome-mRNA-protein ternary complex, we can handle extremely large library sizes. This allows for rapid screening against various animal disease targets, significantly accelerating the discovery phase for novel veterinary biologics and vaccines. For specific design considerations regarding your target species, please consult our technical support team.

Q2. What type of starting materials or input information do we need to provide to initiate the service?

A: To kick off your project, clients typically need to provide specific sequence information, target antigen details, or established immune libraries (if applicable) along with basic project requirements such as desired binding affinity or cross-reactivity specifications. If you are starting from scratch, we can also assist with library generation strategies. Sample quantities and purity requirements vary depending on whether you provide DNA templates or purified proteins, so we strongly suggest reaching out to our technical support staff to confirm the precise preparation guidelines before shipment.

Q3. How long does a typical ribosomal display screening and selection project take to complete?

A: The exact timeline depends heavily on the complexity of the target, the diversity of the initial library, and the number of selection rounds required to achieve the desired enrichment. If your project involves high-throughput screening or downstream validation assays, the timeline may be extended. Please contact our technical support team to discuss a customized project schedule tailored to your goals.

BioVenic provides cutting-edge tools and technologies for the discovery of veterinary therapeutic proteins and peptides, enabling our clients to find effective drugs according to specific veterinary disease targets. If you have questions or need more information about our services, please don't hesitate to contact us. We are committed to delivering expert support for your research and working together to drive advancements in the field of veterinary therapeutic protein and peptide discovery.

Reference

Chen, Jinzhu, et al. "Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display." Pharmaceuticals 19.6 (2026): 967. https://doi.org/10.3390/ph19060967. Used under CC BY 4.0. Without Modification.